Chordate updates on patient study: last patient to start treatment during Q1-2022

The last patient in the study on migraine carried out in Germany and Finland is expected to start treatment during the first quarter of 2022, according to the management of the Finnish part of the study. This after Finland eased pandemic restrictions and the clinics now considers themselves in a position to assess the final phase of recruitment. The clinics’ recruitment activities receive positive responses, and the forecast is that this time frame can be met.

The main purpose of the patient study, which began in 2018, was to enable a CE marking of the company’s preventive treatment of chronic migraine. As Chordate received the CE marking on interim data in May 2021, the purpose is fulfilled, however, a positive result from the patient study is still extremely important for continued marketing activities. The goal is to get a scientific article published. The article is expected to be completed and submitted for scientific review during the third quarter of 2022.

The international patient study on the patented treatment method K.O.S for chronic migraine began in 2018. The study, which is being carried out at nine clinics in Germany and Finland, was suspended due to the covid-19 pandemic in 2020 but has been resumed in stages from the beginning of 2021, completely due to the development of the pandemic.

This disclosure was submitted for publication, through the contact person below, on February 2nd , 2022, at 12:50 pm CET.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy